Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Metabolic medicine

Liver Transplantation and Long-Term Outlook

At a Glance

For children with CPS1 deficiency, liver transplantation restores nitrogen processing in the liver and greatly lowers the risk of future hyperammonemic crises, but it cannot reverse earlier brain injury. Lifelong immune-suppressing medicines and developmental follow-up are still needed.

For many families, liver transplantation represents a significant turning point in managing CPS1 deficiency. Because the CPS1 enzyme primarily lives in the liver, replacing the liver corrects the metabolic defect in that organ [1]. However, it is a complex procedure with its own set of long-term risks and requirements.

The Role of Liver Transplantation

Liver transplantation provides the body with a functioning liver capable of processing nitrogen [2].

  • Reducing Crises: The primary benefit is vastly reducing the risk of future hyperammonemic crises. Once the new liver is functioning, it can typically process nitrogen normally [1][3]. However, graft dysfunction, severe illness, or rejection can still occasionally cause ammonia spikes.
  • Survival Rates: Outcomes are generally favorable for children with urea cycle disorders (UCDs). General US registry cohorts of UCD recipients have shown survival rates around 89-93% in the short term and 10-year survival rates around 87%, though these numbers reflect broader UCD populations and not specifically CPS1 alone [4][5].
  • Dietary Adjustments: After a successful transplant, many children are eventually able to relax their strict low-protein diets and reduce or stop nitrogen-scavenging medications. These changes are always gradual and strictly directed by the transplant and metabolic teams [3][6].

Timing and Decision Making

The decision of when to transplant is highly individualized and involves a multidisciplinary team.

  • Evaluation: Doctors consider a variety of factors, including crisis history, the child’s neurological status, overall growth, response to medical management, surgical risks, waitlist factors, and donor availability [7][8][5].
  • Risks vs. Benefits: Transplantation replaces the daily threat of severe metabolic instability with the risks of major surgery and lifelong medical maintenance. It is not an automatic decision based solely on one high ammonia reading.

Long-Term Outlook and the Brain

It is crucial to understand that while a liver transplant corrects the liver’s function, it cannot reverse or “fix” brain injury that occurred before the surgery [1].

  • Ammonia’s Legacy: A child’s long-term cognitive and developmental outcome is strongly correlated with the severity and duration of early hyperammonemia episodes prior to transplant [9][10]. Higher peak levels and longer coma duration are associated with an increased risk of intellectual disabilities or motor delays [11].
  • Developmental Monitoring: Transplantation prevents further accumulation of damage, but children may still face learning challenges or physical therapy needs based on their early history [1][3]. All children with CPS1 deficiency require regular neurodevelopmental follow-ups [12].

Life After Transplant

A transplant replaces one type of medical management with another.

  • Immunosuppression: To prevent the body from rejecting the new liver, children must take immunosuppressant medications for the rest of their lives [13]. These medications require careful monitoring and carry risks, including an increased susceptibility to infection, kidney strain, and high blood pressure [14][15].
  • Ongoing Care: The child will still need regular visits to a transplant team to ensure the new liver remains healthy [16].

Ultimately, the goal of liver transplantation is to provide a more stable, predictable metabolic life for your child, allowing them to focus on growth and development with a significantly reduced risk of hyperammonemic crises [17].

Common questions in this guide

How can a liver transplant help a child with CPS1 deficiency?
A transplanted liver provides the CPS1 enzyme activity needed to process nitrogen, so it can greatly reduce the risk of future hyperammonemic crises. Ammonia spikes can still occur if the graft is not working well, the child becomes severely ill, or rejection develops.
How do doctors decide when a child with CPS1 deficiency should be evaluated for transplant?
The decision is individualized rather than based on one ammonia result. The team considers crisis history, neurological status, growth, response to medical treatment, surgical risk, waitlist issues, and donor availability.
Will a liver transplant repair brain damage from earlier ammonia crises?
No. A transplant corrects nitrogen processing in the liver and helps prevent further metabolic injury, but it cannot reverse brain injury that occurred before surgery. Long-term development is influenced by the severity and duration of earlier high-ammonia episodes, so regular developmental follow-up remains important.
Can my child stop the low-protein diet or ammonia medicines after transplant?
Many children can gradually relax a strict low-protein diet and reduce or stop nitrogen-scavenging medicines after a successful transplant. Changes must be made slowly and only under the direction of the transplant and metabolic teams.
What medicines and follow-up are needed after a liver transplant?
Children need lifelong immunosuppressant medicines to prevent rejection and regular transplant-team visits to monitor liver health. These medicines can increase the risk of infections, kidney problems, and high blood pressure, so ongoing monitoring is essential.
What are survival rates after transplant for children with CPS1 deficiency?
Registry studies of children with urea cycle disorders report roughly 89–93% short-term survival and about 87% survival at 10 years. These figures include several urea cycle disorders rather than CPS1 deficiency alone, so the transplant center should explain its own results and your child's individual outlook.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What was my child's highest peak ammonia level, and how does that affect their long-term neurodevelopmental outlook?
  2. 2.Given our child's metabolic stability and growth, is now the right time to begin a liver transplant evaluation?
  3. 3.What is this center's specific survival rate for pediatric patients undergoing liver transplantation for urea cycle disorders?
  4. 4.If my child receives a transplant, will they be able to eventually safely reduce ammonia-scavenging medications?
  5. 5.How will my child's developmental progress be monitored over the next several years, and what therapies (OT/PT/Speech) do you recommend?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Role of liver transplantation in urea cycle disorders: Report from a nationwide study in Japan.

    Kido J, Matsumoto S, Häberle J, et al.

    Journal of inherited metabolic disease 2021; (44(6)):1311-1322 doi:10.1002/jimd.12415.

    PMID: 34232532
  2. 2

    Targeting CPS1 in the treatment of Carbamoyl phosphate synthetase 1 (CPS1) deficiency, a urea cycle disorder.

    Diez-Fernandez C, Häberle J

    Expert opinion on therapeutic targets 2017; (21(4)):391-399 doi:10.1080/14728222.2017.1294685.

    PMID: 28281899
  3. 3

    Urea cycle disorders and indications for liver transplantation.

    García Vega M, Andrade JD, Morais A, et al.

    Frontiers in pediatrics 2023; (11()):1103757 doi:10.3389/fped.2023.1103757.

    PMID: 36937980
  4. 4

    Liver Transplantation for Urea Cycle Disorders: Analysis of the United Network for Organ Sharing Database.

    Yu L, Rayhill SC, Hsu EK, Landis CS

    Transplantation proceedings 2015; (47(8)):2413-8.

    PMID: 26518943
  5. 5

    Liver Transplantation in Children with Urea Cycle Disorders: The Importance of Minimizing Waiting Time.

    Ziogas IA, Wu WK, Matsuoka LK, et al.

    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2021; (27(12)):1799-1810 doi:10.1002/lt.26186.

    PMID: 34058057
  6. 6

    Severity-adjusted evaluation of liver transplantation on health outcomes in urea cycle disorders.

    Posset R, Garbade SF, Gleich F, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2024; (26(4)):101039 doi:10.1016/j.gim.2023.101039.

    PMID: 38054409
  7. 7

    Liver transplantation may prevent neurodevelopmental deterioration in high-risk patients with urea cycle disorders.

    Kido J, Matsumoto S, Momosaki K, et al.

    Pediatric transplantation 2017; (21(6)) doi:10.1111/petr.12987.

    PMID: 28608518
  8. 8

    Early liver transplantation in neonatal-onset and moderate urea cycle disorders may lead to normal neurodevelopment.

    Kido J, Matsumoto S, Mitsubuchi H, et al.

    Metabolic brain disease 2018; (33(5)):1517-1523 doi:10.1007/s11011-018-0259-6.

    PMID: 29948653
  9. 9

    Impact of citrulline substitution on clinical outcome after liver transplantation in carbamoyl phosphate synthetase 1 and ornithine transcarbamylase deficiency.

    Aldrian D, Waldner B, Vogel GF, et al.

    Journal of inherited metabolic disease 2024; (47(2)):220-229 doi:10.1002/jimd.12717.

    PMID: 38375550
  10. 10

    Long-term outcome of urea cycle disorders: Report from a nationwide study in Japan.

    Kido J, Matsumoto S, Häberle J, et al.

    Journal of inherited metabolic disease 2021; (44(4)):826-837 doi:10.1002/jimd.12384.

    PMID: 33840128
  11. 11

    Impact of Diagnosis and Therapy on Cognitive Function in Urea Cycle Disorders.

    Posset R, Gropman AL, Nagamani SCS, et al.

    Annals of neurology 2019; (86(1)):116-128 doi:10.1002/ana.25492.

    PMID: 31018246
  12. 12

    Long-term follow-up of children with carbamoyl phosphate synthase 1 deficiency detected in newborn screening.

    Zhang Z, Tong F, Chen C, et al.

    Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences 2023; (52(6)):721-726 doi:10.3724/zdxbyxb-2023-0359.

    PMID: 37986659
  13. 13

    Pediatric Liver Transplantation: Long-Term Follow-Up Issues.

    Bellini MI, Lauro A, D'Andrea V, Marino IR

    Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation 2022; (20(Suppl 3)):27-35 doi:10.6002/ect.PediatricSymp2022.L16.

    PMID: 35570596
  14. 14

    Immunosuppression in pediatric liver transplant recipients: Unique aspects.

    Miloh T, Barton A, Wheeler J, et al.

    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2017; (23(2)):244-256 doi:10.1002/lt.24677.

    PMID: 27874250
  15. 15

    Health-related quality of life after pediatric liver transplantation: A systematic review.

    Parmar A, Vandriel SM, Ng VL

    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2017; (23(3)):361-374 doi:10.1002/lt.24696.

    PMID: 28006876
  16. 16

    Report of 3 Patients With Urea Cycle Defects Treated With Related Living-Donor Liver Transplant.

    Özçay F, Barış Z, Moray G, et al.

    Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation 2015; (13 Suppl 3()):126-30 doi:10.6002/ect.tdtd2015.P69.

    PMID: 26640932
  17. 17

    The burden of pharmacological treatment on health-related quality of life in people with a urea cycle disorder: a qualitative study.

    Yeowell G, Burns DS, Fatoye F

    Journal of patient-reported outcomes 2021; (5(1)):110 doi:10.1186/s41687-021-00387-x.

    PMID: 34694515

This page is for informational purposes only and does not constitute medical advice. A metabolic and transplant team should advise you about timing, risks, medicines, and your child's individual outlook.

Get notified when new evidence is published on Carbamoyl-phosphate synthetase 1 deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.